EP Patent

EP3310760B8 — Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders

Assigned to Arena Pharmaceuticals Inc · Expires 2022-10-19 · 4y expired

What this patent protects

Patent listed against Velsipity.

Drugs covered by this patent

Patent Metadata

Patent number
EP3310760B8
Jurisdiction
EP
Classification
—
Expires
2022-10-19
Drug substance claim
No
Drug product claim
No
Assignee
Arena Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.